leisure time -WSS

leisure time

author：explore 2025-09-02 08:08:55 - browse：25

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Roche's accidental data boosts hopes for anti

focus

hotspot

WSS

Kellogg’s is going to war over Mexico’s nutrition label rules

Listen: Vivek Ramaswamy's star turn & leaky drug data

Eyeing GLP

Vivek Ramaswamy made waves in the debate, much as in biotech

Digital health: a case of mistaken identity

FDA advisory panel to debate high blood pressure devices

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Medical leaders decry Supreme Court decision on affirmative action

FDA advisory panel to debate high blood pressure devices

The cancer drug shortage isn’t new — and neither are the solutions

Biogen joins immunology wave with $1.15 billion acquisition of HI

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Addressing health care workers' trauma can help fight burnout

DIEP, the 'gold standard' of breast reconstruction, is under threat

ASCO eve: Let’s set the table for this year's meeting

hotspot

Fentanyl is making it harder to start addiction treatment

Listen: More tumult at BIO & coercive care for sickle cell patients

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Study: Spinal cord stimulation helps patients with paralysis walk again

Eyeing GLP

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

focus

hotspot

focus

hotspot